Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study

Aihara M, Lu F, Kawata H, Iwata A, Odani-Kawabata N.

2021
Japanese journal of ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Ophthalmology, University of Tokyo, Tokyo, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA. Fenghe.Lu@santen.com; Santen Pharmaceutical Co., Ltd., Osaka, Japan; Santen Inc., 6401 Hollis Street, Suite 125, Emeryville, CA, 94608, USA

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022